Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer.
COVID-19
Cancer
Clinical efficacy
Prevention
SARS-CoV-2
Vaccines
Journal
European journal of cancer (Oxford, England : 1990)
ISSN: 1879-0852
Titre abrégé: Eur J Cancer
Pays: England
ID NLM: 9005373
Informations de publication
Date de publication:
08 2022
08 2022
Historique:
received:
11
03
2022
revised:
18
04
2022
accepted:
25
04
2022
pubmed:
16
6
2022
medline:
20
7
2022
entrez:
15
6
2022
Statut:
ppublish
Résumé
Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined. Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients. 2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320). This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.
Sections du résumé
BACKGROUND
Although SARS-CoV-2 vaccines immunogenicity in patients with cancer has been investigated, whether they can significantly improve the severity of COVID-19 in this specific population is undefined.
METHODS
Capitalizing on OnCovid (NCT04393974) registry data we reported COVID-19 mortality and proxies of COVID-19 morbidity, including post-COVID-19 outcomes, according to the vaccination status of the included patients.
RESULTS
2090 eligible patients diagnosed with COVID-19 between 02/2020 and 11/2021 were included, of whom 1930 (92.3%) unvaccinated, 91 (4.4%) fully vaccinated and 69 (3.3%) partially vaccinated. With the exception of a higher prevalence of patients from the UK (p = 0.0003) and receiving systemic anticancer therapy at COVID-19 diagnosis (p = 0.0082) among fully vaccinated patients, no demographics/oncological features were associated with vaccination status. The 14-days case fatality rate (CFR) (5.5% vs 20.7%, p = 0.0004) and the 28-days CFR (13.2% vs 27.4%, p = 0.0028) demonstrated a significant improvement for fully vaccinated patients in comparison with unvaccinated patients. The receipt of prior full vaccination was also associated with reduced symptomatic COVID-19 (79.1% vs 88.5%, p = 0.0070), need of COVID-19 oriented therapy (34.9% vs 63.2%, p < 0.0001), complications from COVID-19 (28.6% vs 39.4%, p = 0.0379), hospitalizations due to COVID-19 (42.2% vs 52.5%, p = 0.0007) and oxygen therapy requirement (35.7% vs 52%, p = 0.0036). Following Inverse Probability Treatment Weighting (IPTW) procedure no statistically significant difference according to the vaccination status was confirmed; however, all COVID-19 related outcomes were concordantly in favour of full vaccination. Among the 1228 (58.8%) patients who underwent a formal reassessment at participating centres after COVID-19 resolution, fully vaccinated patients experienced less sequelae than unvaccinated patients (6.7% vs 17.2%, p = 0.0320).
CONCLUSIONS
This analysis provides initial evidence in support of the beneficial effect of SARS-CoV-2 vaccines against morbidity and mortality from COVID-19 in patients with cancer.
Identifiants
pubmed: 35704976
pii: S0959-8049(22)00276-3
doi: 10.1016/j.ejca.2022.04.036
pmc: PMC9124924
pii:
doi:
Substances chimiques
COVID-19 Vaccines
0
Banques de données
ClinicalTrials.gov
['NCT04393974']
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
64-74Investigateurs
David J Pinato
(DJ)
Joanne S Evans
(JS)
Judith Swallow
(J)
Alessio Cortellini
(A)
Georgina Hanbury
(G)
Chris Chung
(C)
Meera Patel
(M)
Gino Dettorre
(G)
Diego Ottaviani
(D)
Amani Chowdhury
(A)
Alvin Jx Lee
(AJ)
Christopher Ct Sng
(CC)
Tamara Yu
(T)
Marianne Shawe-Taylor
(M)
Hamish Dc Bain
(HD)
Alasdair Sinclair
(A)
Lee Cooper
(L)
Lucy Rogers
(L)
Katherine Belessiotis
(K)
Cian Murphy
(C)
Samira Bawany
(S)
Saira Khalique
(S)
Ramis Andaleeb
(R)
Mark Bower
(M)
Alessia Dalla Pria
(A)
Rachel Sharkey
(R)
Thomas Newsom-Davis
(T)
Saorise Dolly
(S)
Ailsa Sita-Lumsde
(A)
Eleanor Apthorp
(E)
Eleanor Jones
(E)
Mieke Van Hemelrijck
(M)
Charlotte Moss
(C)
Beth Russell
(B)
Eleanor Apthorp
(E)
Nikolaos Diamantis
(N)
Uma Mukherjee
(U)
Sarah Townsend
(S)
Amanda Jackson
(A)
Angela Loizidou
(A)
Martine Piccart
(M)
Aleix Prat
(A)
Claudia A Cruz
(CA)
Roxana Reyes
(R)
Elia Segui
(E)
Javier Marco-Hernández
(J)
Margarita Viladot
(M)
Josep Tabernero
(J)
Juan Aguilar-Company
(J)
Isabel Ruiz-Camps
(I)
Laura Fox
(L)
David Garcia Illescas
(D)
Nadia Saoudi
(N)
Oriol Mirallas
(O)
Elisa Roldán
(E)
Joan Brunet
(J)
MCarmen Carmona Garcia
(M)
Robert Fort-Culillas
(R)
Raquel Liñan
(R)
Nadia Harbeck
(N)
Rachel Wuerstlein
(R)
Franziska Henze
(F)
Sven Mahner
(S)
Ricard Mesia
(R)
Eudald Felip
(E)
Andrea Plaja
(A)
Marc Cucurull
(M)
Ramon Salazar
(R)
Anna Sureda
(A)
Clara Maluquer
(C)
Alessandra Gennari
(A)
Federica Biello
(F)
Francesca D'Avanzo
(F)
Gianluca Gaidano
(G)
Riccardo Bruna
(R)
Andrea Patriarca
(A)
Daniela Ferrante
(D)
Lorenza Scotti
(L)
Marco Krengly
(M)
Paolo Pedrazzoli
(P)
Gianpiero Rizzo
(G)
Alexia Bertuzzi
(A)
Sabrina Rossi
(S)
Andrea Marrari
(A)
Armando Santoro
(A)
Lorenza Rimassa
(L)
Federica Grosso
(F)
Vittorio Fusco
(V)
Sara Delfanti
(S)
Antonio Maconi
(A)
Marta Betti
(M)
Bruno Vincenzi
(B)
Giuseppe Tonini
(G)
Alberto Zambelli
(A)
Carlo Tondini
(C)
Vittoria Fotia
(V)
Lorenzo Chiudinelli
(L)
Michela Franchi
(M)
Michela Libertini
(M)
Rossella Bertulli
(R)
Salvatore Provenzano
(S)
Daniele Generali
(D)
Salvatore Grisanti
(S)
Alice Baggi
(A)
Valeria Tovazzi
(V)
Corrado Ficorella
(C)
Giampiero Porzio
(G)
Alessandro Parisi
(A)
Paola Queirolo
(P)
Maristella Saponara
(M)
Raffaele Giusti
(R)
Marco Filetti
(M)
Francesca Mazzoni
(F)
Federica Zoratto
(F)
Marco Tucci
(M)
Rossana Berardi
(R)
Luca Cantini
(L)
Francesco Paoloni
(F)
Annalisa Guida
(A)
Sergio Bracarda
(S)
Clara Martinez-Vila
(C)
Maria Iglesias
(M)
Ana Sanchez de Torre
(A)
Matteo Lambertini
(M)
Marta Perachino
(M)
Fanny Pommeret
(F)
Emeline Colomba
(E)
Informations de copyright
Copyright © 2022 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest statement The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: As corresponding author of the abovementioned manuscript, I declare on behalf of my co-authors the following conflict of interests: David J Pinato received lecture fees from ViiV Healthcare, Bayer Healthcare, BMS, Roche, EISAI, Falk Foundation, travel expenses from BMS and Bayer Healthcare; consulting fees for Mina Therapeutics, EISAI, Roche, DaVolterra and Astra Zeneca; research funding (to institution) from MSD and BMS.Aleix Prat has declared personal honoraria from Pfizer, Roche, MSD Oncology, Eli Lilly, and Daiichi Sankyo; travel, accommodations, and expenses paid by Daiichi Sankyo; research funding from Roche and Novartis; and consulting/advisory role for NanoString Technologies, Amgen, Roche, Novartis, Pfizer and Bristol-Myers Squibb.Matteo Lambertini acted as consultant for Roche, Novartis, Lilly, AstraZeneca, Exact Sciences, MSD, Pfizer, Seagen and received speaker honoraria from Roche, Novartis, Lilly, Pfizer, Takeda, Ipsen and Sandoz outside the submitted work.Joan Brunet has declared consulting/advisory role for MSD and Astra Zeneca.Alessandra Gennari has declared consulting/advisory role for Roche, MSD, Eli Lilly, Pierre Fabre, EISAI, and Daichii Sankyo; speakers bureau for Eisai, Novartis, Eli Lilly, Roche, Teva, Gentili, Pfizer, Astra Zeneca, Celgene, and Daichii Sankyo; research funds: EISAI, Eli Lilly, and Roche. CMV has received travel grants and other honoraria from BMS, MSD, Novartis and Roche.Gianluca Gaidano has declared consulting/advisory role for Janssen, Abbvie, Astra-Zeneca and BeiGene, and speaker fees from Janssen and Abbvie.Lorenza Rimassa received consulting fees from Taiho Oncology, Servier, Amgen, ArQule, AstraZeneca, Basilea, Bayer, BMS, Celgene, Eisai, Exelixis, Genenta, Hengrui, Incyte, Ipsen, IQVIA, Lilly, MSD, Nerviano Medical Sciences, Roche, Sanofi, Zymeworks; lecture fees from AbbVie, Amgen, Bayer, Eisai, Gilead, Incyte, Ipsen, Lilly, Merck Serono, Roche, Sanofi; travel expenses from Ipsen; and institutional research funding from Agios, ARMO BioSciences, AstraZeneca, BeiGene, Eisai, Exelixis, Fibrogen, Incyte, Ipsen, Lilly, MSD, Nerviano Medical Sciences, Roche, Zymeworks.Joseph Tabernero reported consulting fees from Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, Inspirna Inc, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Ona Therapeutics, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Scandion Oncology, Servier, Sotio Biotech, Taiho, Tessa Therapeutics and TheraMyc. He also reported speaker's fees from Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER). He also declared institutional research support from Amgen Inc, Array Biopharma Inc, AstraZeneca Pharmaceuticals LP, BeiGene, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Debiopharm International SA, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Janssen-Cilag SA, MedImmune, Menarini, Merck Health KGAA, Merck Sharp & Dohme, Merus NV, Mirati, Novartis Farmacéutica SA, Pfizer, Pharma Mar, Sanofi Aventis Recherche & Développement, Servier, Taiho Pharma USA Inc, Spanish Association Against Cancer Scientific Foundation and Cancer Research UK.Alessio Cortellini received consulting fees from MSD, BMS, AstraZeneca, Roche; speakers' fee from AstraZeneca, MSD, Novartis and Eisai.All remaining authors have declared no conflicts of interest.London, April 18th, 2022.
Références
Cancer Discov. 2020 Jul 31;:
pubmed: 32737082
Cancer Cell. 2021 Aug 9;39(8):1091-1098.e2
pubmed: 34214473
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Eur J Cancer. 2021 Jun;150:190-202
pubmed: 33932726
J Med Virol. 2022 May;94(5):1825-1832
pubmed: 35023191
Nat Cancer. 2021 Dec;2(12):1321-1337
pubmed: 35121900
Eur J Cancer. 2022 Jan;160:243-260
pubmed: 34794855
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
Lancet Oncol. 2021 Dec;22(12):1669-1680
pubmed: 34741822
Lancet Reg Health Eur. 2021 Nov;10:100208
pubmed: 34514454
Lancet Oncol. 2020 Jul;21(7):914-922
pubmed: 32539942
Cancers (Basel). 2020 Jul 08;12(7):
pubmed: 32650523
N Engl J Med. 2021 Aug 12;385(7):585-594
pubmed: 34289274
Ann Oncol. 2022 Mar;33(3):340-346
pubmed: 34958894
Lancet Oncol. 2020 Jun;21(6):748-750
pubmed: 32359404
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246
N Engl J Med. 2021 Jan 7;384(1):80-82
pubmed: 33270381
Lancet. 2021 Jan 9;397(10269):99-111
pubmed: 33306989
N Engl J Med. 2021 Jun 10;384(23):2187-2201
pubmed: 33882225
Cell. 2022 Feb 3;185(3):447-456.e11
pubmed: 35026151
Lancet Oncol. 2021 Dec;22(12):1681-1691
pubmed: 34767759
Crit Rev Oncol Hematol. 2021 Jul;163:103365
pubmed: 34052423
JCO Glob Oncol. 2020 Jun;6:799-808
pubmed: 32511066
Nat Cancer. 2021 Dec;2(12):1305-1320
pubmed: 35121899
JAMA Oncol. 2022 Jan 1;8(1):114-122
pubmed: 34817562
Nat Microbiol. 2021 Sep;6(9):1140-1149
pubmed: 34290390
J Immunother Cancer. 2021 Mar;9(3):
pubmed: 33753569
N Engl J Med. 2021 Feb 4;384(5):403-416
pubmed: 33378609
Nat Rev Clin Oncol. 2021 Jan;18(1):3-4
pubmed: 33097915
Cancer Cell. 2022 Jan 10;40(1):103-108.e2
pubmed: 34990570